{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:35:09Z","timestamp":1793414109549,"version":"4.5.0"},"reference-count":47,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Intern Med"],"published-print":{"date-parts":[[2026,3,1]]},"abstract":"<jats:sec>\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>The prevalence of pathogenic or likely pathogenic variants (PVs) in breast cancer susceptibility genes in the US population\u2014regardless of family history risk factors\u2014remains largely unknown because population-based genetic screening is not routinely performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To identify the prevalence of PVs in a large cohort of women offered criteria-independent genetic testing and to evaluate the relationship of test positivity to family history and other patient characteristics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>The Women Informed to Screen Depending on Measures of Risk (WISDOM) randomized clinical trial enrolled women without breast cancer aged 40 to 74 years between August 2016 and February 2023 in a pragmatic randomized screening trial comparing annual screening mammography with personalized risk-based screening. Data were analyzed from August 2023 to November 2025.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Exposures<\/jats:title>\n                    <jats:p>\n                      All women in the personalized screening arm were offered germline testing for 9 breast cancer susceptibility genes:\n                      <jats:italic>BRCA1<\/jats:italic>\n                      ,\n                      <jats:italic>BRCA2<\/jats:italic>\n                      ,\n                      <jats:italic>ATM<\/jats:italic>\n                      ,\n                      <jats:italic>CHEK2<\/jats:italic>\n                      ,\n                      <jats:italic>PALB2<\/jats:italic>\n                      ,\n                      <jats:italic>CDH1<\/jats:italic>\n                      ,\n                      <jats:italic>PTEN<\/jats:italic>\n                      ,\n                      <jats:italic>STK11<\/jats:italic>\n                      , and\n                      <jats:italic>TP53<\/jats:italic>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>The prevalence of PVs in the trial and the distribution of self-reported demographic and family history data in this subpopulation of carriers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 23\u202f098 women who completed germline genetic testing (mean [SD] age, 54.3 [9.6] years), 714 (3.1%) carried a PV. Excluding 109 who were previously aware of their PV, the detection rate was 2.6%. PVs were most common in\n                      <jats:italic>CHEK2<\/jats:italic>\n                      (337 [1.5%]) and\n                      <jats:italic>ATM<\/jats:italic>\n                      (101 [0.4%]) but less common in higher-penetrance genes (\n                      <jats:italic>BRCA1<\/jats:italic>\n                      , 33 [0.1%];\n                      <jats:italic>BRCA2<\/jats:italic>\n                      , 82 [0.4%];\n                      <jats:italic>PALB2<\/jats:italic>\n                      , 44 [0.2%]). PVs in the\n                      <jats:italic>CDH1<\/jats:italic>\n                      ,\n                      <jats:italic>PTEN<\/jats:italic>\n                      ,\n                      <jats:italic>STK11<\/jats:italic>\n                      , and\n                      <jats:italic>TP53<\/jats:italic>\n                      genes were rare (less than 0.1%). Notably, 180 of 605 women with PVs (29.8%) did not report a first-degree or second-degree female relative with breast or ovarian cancer, male relative with breast cancer, or Jewish ancestry.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>In this secondary analysis of the WISDOM trial, criteria-independent genetic testing in a pragmatic trial identified a substantial number of women with clinically actionable results, many of whom would not have qualified for genetic testing under current guidelines. These findings support broader access to genetic testing as part of personalized breast cancer risk assessment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>\n                      ClinicalTrials.gov Identifier:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT02620852\">NCT02620852<\/jats:ext-link>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamainternmed.2025.7323","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T19:30:16Z","timestamp":1765567816000},"page":"344","source":"Crossref","is-referenced-by-count":7,"title":["Germline Pathogenic Variants Among Women Without a History of Breast Cancer"],"prefix":"10.1001","volume":"186","author":[{"given":"Kirkpatrick B.","family":"Fergus","sequence":"first","affiliation":[{"name":"Cancer Genetics and Prevention Program, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine S.","family":"Ross","sequence":"additional","affiliation":[{"name":"Cancer Genetics and Prevention Program, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maren T.","family":"Scheuner","sequence":"additional","affiliation":[{"name":"San Francisco VA Health Care System, San Francisco, California"},{"name":"Department of Medicine\/Hematology-Oncology, University of California, San Francisco"},{"name":"Department of Pediatrics\/Medical Genetics, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amie M.","family":"Blanco","sequence":"additional","affiliation":[{"name":"Cancer Genetics and Prevention Program, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey A.","family":"Tice","sequence":"additional","affiliation":[{"name":"Division of General Internal Medicine, Department of Medicine, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elad","family":"Ziv","sequence":"additional","affiliation":[{"name":"Cancer Genetics and Prevention Program, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiwey","family":"Shieh","sequence":"additional","affiliation":[{"name":"Department of Population Health Sciences, Weill Cornell Medicine, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"van \u2018t Veer","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olufunmilayo I.","family":"Olopade","sequence":"additional","affiliation":[{"name":"Section of Hematology\/Oncology, Department of Medicine, University of Chicago, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah L.","family":"Goodman","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, University of California, Irvine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry S.","family":"Tong","sequence":"additional","affiliation":[{"name":"Cancer Genetics and Prevention Program, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Harvey","sequence":"additional","affiliation":[{"name":"Sanford Health, Sioux Falls, South Dakota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"DeRosa","sequence":"additional","affiliation":[{"name":"Moores UCSD Cancer Center, University of California, San Diego, La Jolla"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larissa","family":"Risty","sequence":"additional","affiliation":[{"name":"Edith Sanford Breast Cancer, Sanford Health, Fargo, North Dakota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Silver","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Department of Medicine, David Geffen School of Medicine at UCLA, University of California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Kaster","sequence":"additional","affiliation":[{"name":"Edith Sanford Breast Cancer, Sanford Health, Fargo, North Dakota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison Stover","family":"Fiscalini","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Blum","sequence":"additional","affiliation":[{"name":"Cancer Genetics and Prevention Program, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Heise","sequence":"additional","affiliation":[{"name":"Department of Population Health Sciences, Weill Cornell Medicine, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah","family":"Sabacan","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Heditsian","sequence":"additional","affiliation":[{"name":"Breast Science Advocacy Core, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susie","family":"Brain","sequence":"additional","affiliation":[{"name":"Breast Science Advocacy Core, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Petruse","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Department of Medicine, David Geffen School of Medicine at UCLA, University of California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Eklund","sequence":"additional","affiliation":[{"name":"Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Hiatt","sequence":"additional","affiliation":[{"name":"Department of Epidemiology & Biostatistics, University of California, San Francisco"},{"name":"Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander D.","family":"Borowsky","sequence":"additional","affiliation":[{"name":"University of California, Davis, Sacramento"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arash","family":"Naeim","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Department of Medicine, David Geffen School of Medicine at UCLA, University of California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah L.","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Pathology & Laboratory Medicine, University of California, Irvine"},{"name":"Department of Epidemiology & Biostatistics, University of California, Irvine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea Z.","family":"LaCroix","sequence":"additional","affiliation":[{"name":"Herbert Wertheim School of Public Health and Human Longevity Science, University of California, San Diego, La Jolla"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara A.","family":"Parker","sequence":"additional","affiliation":[{"name":"Moores UCSD Cancer Center, University of California, San Diego, La Jolla"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael","family":"Lancaster","sequence":"additional","affiliation":[{"name":"University of Alabama at Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Esserman","sequence":"additional","affiliation":[{"name":"Diagnostic Center of Miami, Miami, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Wenger","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Department of Medicine, David Geffen School of Medicine at UCLA, University of California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vignesh","family":"Arasu","sequence":"additional","affiliation":[{"name":"Division of Research, Kaiser Permanente Division of Research, Pleasanton, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoda","family":"Anton-Culver","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, University of California, Irvine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura J.","family":"Esserman","sequence":"additional","affiliation":[{"name":"Cancer Genetics and Prevention Program, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Madlensky","sequence":"additional","affiliation":[{"name":"Moores UCSD Cancer Center, University of California, San Diego, La Jolla"},{"name":"Division of Genomics and Precision Medicine, Department of Medicine, University of California, San Diego, La Jolla"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"21","key":"ioi250090r1","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1200\/JCO.24.00662","article-title":"Selection of germline genetic testing panels in patients with cancer: ASCO guideline.","volume":"42","author":"Tung","year":"2024","journal-title":"J Clin Oncol"},{"issue":"7","key":"ioi250090r2","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1001\/jama.2019.10987","article-title":"Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer: US Preventive Services Task Force recommendation statement.","volume":"322","author":"Owens","year":"2019","journal-title":"JAMA"},{"issue":"4","key":"ioi250090r3","doi-asserted-by":"publisher","first-page":"380","DOI":"10.6004\/jnccn.2020.0017","article-title":"NCCN Guidelines Insights: genetic\/familial high-risk assessment: breast, ovarian, and pancreatic, version 1.2020.","volume":"18","author":"Daly","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"issue":"5","key":"ioi250090r4","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1200\/JCO.23.02225","article-title":"Germline testing in patients with breast cancer: ASCO\u2013Society of Surgical Oncology guideline.","volume":"42","author":"Bedrosian","year":"2024","journal-title":"J Clin Oncol"},{"issue":"1","key":"ioi250090r5","doi-asserted-by":"publisher","first-page":"9","DOI":"10.6004\/jnccn.2017.0003","article-title":"NCCN Guidelines Insights: genetic\/familial high-risk assessment: breast and ovarian, version 2.2017.","volume":"15","author":"Daly","year":"2017","journal-title":"J Natl Compr Canc Netw"},{"issue":"3","key":"ioi250090r7","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1093\/jamia\/ocad243","article-title":"Barriers and facilitators to the implementation of family cancer history collection tools in oncology clinical practices.","volume":"31","author":"Allen","year":"2024","journal-title":"J Am Med Inform Assoc"},{"issue":"3","key":"ioi250090r8","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1158\/1055-9965.EPI-09-1085","article-title":"Perceived cancer risk: why is it lower among nonwhites than whites?","volume":"19","author":"Orom","year":"2010","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"2","key":"ioi250090r9","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1002\/cncr.23173","article-title":"Family history of cancer: is it an accurate indicator of cancer risk in the immigrant population?","volume":"112","author":"Orom","year":"2008","journal-title":"Cancer"},{"issue":"3","key":"ioi250090r10","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1007\/s11606-006-0087-y","article-title":"Missed opportunities: family history and behavioral risk factors in breast cancer risk assessment among a multiethnic group of women.","volume":"22","author":"Karliner","year":"2007","journal-title":"J Gen Intern Med"},{"issue":"3","key":"ioi250090r11","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1002\/jgc4.1264","article-title":"Ethnic disparities in the frequency of cancer reported in family histories.","volume":"29","author":"Maves","year":"2020","journal-title":"J Genet Couns"},{"issue":"5","key":"ioi250090r12","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1056\/NEJMoa2005936","article-title":"A population-based study of genes previously implicated in breast cancer.","volume":"384","author":"Hu","year":"2021","journal-title":"N Engl J Med"},{"issue":"13","key":"ioi250090r13","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1200\/JCO.2015.65.0747","article-title":"Frequency of germline mutations in 25 cancer susceptibility genes in a sequential series of patients with breast cancer.","volume":"34","author":"Tung","year":"2016","journal-title":"J Clin Oncol"},{"issue":"13","key":"ioi250090r14","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1200\/JCO.19.02190","article-title":"Evaluation of germline genetic testing criteria in a hospital-based series of women with breast cancer.","volume":"38","author":"Yadav","year":"2020","journal-title":"J Clin Oncol"},{"issue":"9","key":"ioi250090r15","doi-asserted-by":"publisher","first-page":"e2232787","DOI":"10.1001\/jamanetworkopen.2022.32787","article-title":"Clinical utility of universal germline genetic testing for patients with breast cancer.","volume":"5","author":"Whitworth","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"4","key":"ioi250090r16","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1001\/jamaoncol.2023.6944","article-title":"MRI surveillance and breast cancer mortality in women with BRCA1 and BRCA2 sequence variations.","volume":"10","author":"Lubinski","year":"2024","journal-title":"JAMA Oncol"},{"issue":"5","key":"ioi250090r17","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa031759","article-title":"Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition.","volume":"351","author":"Kriege","year":"2004","journal-title":"N Engl J Med"},{"issue":"11","key":"ioi250090r18","doi-asserted-by":"publisher","first-page":"3116","DOI":"10.1002\/cncr.23913","article-title":"The American Cancer Society guidelines for breast screening with magnetic resonance imaging: an argument for genetic testing.","volume":"113","author":"Murphy","year":"2008","journal-title":"Cancer"},{"issue":"2","key":"ioi250090r19","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1200\/JCO.2009.22.7991","article-title":"Survival analysis of cancer risk reduction strategies for BRCA1\/2 mutation carriers.","volume":"28","author":"Kurian","year":"2010","journal-title":"J Clin Oncol"},{"issue":"9","key":"ioi250090r20","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1001\/jama.2010.1237","article-title":"Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.","volume":"304","author":"Domchek","year":"2010","journal-title":"JAMA"},{"issue":"15","key":"ioi250090r21","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1200\/JCO.2013.53.2820","article-title":"Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation.","volume":"32","author":"Finch","year":"2014","journal-title":"J Clin Oncol"},{"issue":"4","key":"ioi250090r22","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1001\/jamaoncol.2020.7995","article-title":"Association of risk-reducing salpingo-oophorectomy with breast cancer risk in women with BRCA1 and BRCA2 pathogenic variants.","volume":"7","author":"Choi","year":"2021","journal-title":"JAMA Oncol"},{"issue":"3","key":"ioi250090r23","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1007\/s10897-014-9805-5","article-title":"Aligning policy to promote cascade genetic screening for prevention and early diagnosis of heritable diseases.","volume":"24","author":"George","year":"2015","journal-title":"J Genet Couns"},{"issue":"4","key":"ioi250090r24","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1001\/jamaoncol.2021.6204","article-title":"Breast cancer screening strategies for women with ATM, CHEK2, and PALB2 pathogenic variants: a comparative modeling analysis.","volume":"8","author":"Lowry","year":"2022","journal-title":"JAMA Oncol"},{"issue":"10","key":"ioi250090r25","doi-asserted-by":"publisher","DOI":"10.1016\/j.gim.2023.100870","article-title":"Management of individuals with germline pathogenic\/likely pathogenic variants in CHEK2: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG).","volume":"25","author":"Hanson","year":"2023","journal-title":"Genet Med"},{"issue":"9","key":"ioi250090r26","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jama.2017.11022","article-title":"The potential and challenges of expanded germline testing in clinical oncology.","volume":"318","author":"Van Allen","year":"2017","journal-title":"JAMA"},{"key":"ioi250090r27","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/s41523-017-0035-5","article-title":"The WISDOM study: breaking the deadlock in the breast cancer screening debate.","volume":"3","author":"Esserman","year":"2017","journal-title":"NPJ Breast Cancer"},{"issue":"9","key":"ioi250090r28","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1038\/nrclinonc.2016.50","article-title":"Population-based screening for cancer: hope and hype.","volume":"13","author":"Shieh","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"ioi250090r29","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.jmoldx.2019.03.001","article-title":"Multi-gene panel testing of 23,179 individuals for hereditary cancer risk identifies pathogenic variant carriers missed by current genetic testing guidelines.","volume":"21","author":"Neben","year":"2019","journal-title":"J Mol Diagn"},{"key":"ioi250090r30","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.24784","article-title":"Risk-based vs annual breast cancer screening: the WISDOM randomized clinical trial.","author":"Esserman","journal-title":"JAMA"},{"issue":"3","key":"ioi250090r31","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s10549-016-3953-2","article-title":"Breast cancer risk prediction using a clinical risk model and polygenic risk score.","volume":"159","author":"Shieh","year":"2016","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"ioi250090r32","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s13073-025-01524-7","article-title":"Integrating breast cancer polygenic risk scores at scale in the WISDOM study: a national randomized personalized screening trial.","volume":"17","author":"Fergus","year":"2025","journal-title":"Genome Med"},{"issue":"10","key":"ioi250090r33","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/j.annonc.2024.07.244","article-title":"Population-based germline breast cancer gene association studies and meta-analysis to inform wider mainstream testing.","volume":"35","author":"Rowlands","year":"2024","journal-title":"Ann Oncol"},{"issue":"4","key":"ioi250090r34","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1038\/s41436-020-01034-4","article-title":"A state-based approach to genomics for rare disease and population screening.","volume":"23","author":"East","year":"2021","journal-title":"Genet Med"},{"issue":"24","key":"ioi250090r35","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1200\/JCO.19.00160","article-title":"The time for mainstreaming germline testing for patients with breast cancer is now.","volume":"37","author":"Rajagopal","year":"2019","journal-title":"J Clin Oncol"},{"issue":"1","key":"ioi250090r36","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1080\/13696998.2022.2152233","article-title":"A review of the cost-effectiveness of genetic testing for germline variants in familial cancer.","volume":"26","author":"Teppala","year":"2023","journal-title":"J Med Econ"},{"issue":"22","key":"ioi250090r37","doi-asserted-by":"publisher","first-page":"5612","DOI":"10.3390\/cancers13225612","article-title":"Universal germline testing of unselected cancer patients detects pathogenic variants missed by standard guidelines without increasing healthcare costs.","volume":"13","author":"Perkins","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"9","key":"ioi250090r38","doi-asserted-by":"publisher","first-page":"3214","DOI":"10.1158\/1078-0432.CCR-08-3128","article-title":"The breast cancer susceptibility mutation PALB2 1592delT is associated with an aggressive tumor phenotype.","volume":"15","author":"Heikkinen","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"24","key":"ioi250090r39","doi-asserted-by":"publisher","first-page":"7357","DOI":"10.1158\/1078-0432.CCR-07-0689","article-title":"BRCA1 mutation and young age predict fast breast cancer growth in the Dutch, United Kingdom, and Canadian magnetic resonance imaging screening trials.","volume":"13","author":"Tilanus-Linthorst","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"23","key":"ioi250090r40","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1001\/jama.297.23.2587","article-title":"Limited family structure and BRCA gene mutation status in single cases of breast cancer.","volume":"297","author":"Weitzel","year":"2007","journal-title":"JAMA"},{"issue":"6","key":"ioi250090r41","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1038\/s41436-020-01082-w","article-title":"DNA-based screening and population health: a points to consider statement for programs and sponsoring organizations from the American College of Medical Genetics and Genomics (ACMG).","volume":"23","author":"Murray","year":"2021","journal-title":"Genet Med"},{"issue":"28","key":"ioi250090r42","doi-asserted-by":"publisher","first-page":"3747","DOI":"10.1200\/JCO.2010.34.0778","article-title":"Risk of breast cancer in women with a CHEK2 mutation with and without a family history of breast cancer.","volume":"29","author":"Cybulski","year":"2011","journal-title":"J Clin Oncol"},{"issue":"1","key":"ioi250090r43","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1007\/s40615-023-01526-4","article-title":"Genetic testing for cancer risk and perceived importance of genetic information among US population by race and ethnicity: a cross-sectional study.","volume":"11","author":"Hong","year":"2024","journal-title":"J Racial Ethn Health Disparities"},{"key":"ioi250090r44","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.bpobgyn.2020.02.007","article-title":"Population-based genetic testing for women\u2019s cancer prevention.","volume":"65","author":"Evans","year":"2020","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"issue":"3","key":"ioi250090r45","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.0917","article-title":"Genomic screening at a single health system.","volume":"8","author":"Savatt","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"6","key":"ioi250090r46","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1002\/jgc4.1617","article-title":"A qualitative study of unaffected ATM and CHEK2 carriers: how participants make meaning of \u2018moderate risk\u2019 genetic results in a population breast cancer screening trial.","volume":"31","author":"James","year":"2022","journal-title":"J Genet Couns"},{"issue":"12","key":"ioi250090r47","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1001\/jama.292.12.1480","article-title":"Does this patient have a family history of cancer? an evidence-based analysis of the accuracy of family cancer history.","volume":"292","author":"Murff","year":"2004","journal-title":"JAMA"},{"key":"ioi250090r6","volume-title":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Genetic\/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic and Prostate V.2.2026","author":"National Comprehensive Cancer Network","year":"2025"}],"container-title":["JAMA Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/articlepdf\/2842682\/jamainternal_fergus_2025_oi_250090_1771882363.3743.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T16:01:16Z","timestamp":1772467276000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/fullarticle\/2842682"}},"subtitle":["A Secondary Analysis of the WISDOM Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2026,3,1]]},"references-count":47,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamainternmed.2025.7323","relation":{},"ISSN":["2168-6106"],"issn-type":[{"value":"2168-6106","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,1]]}}}